Servier completes the acquisition of Edgewise Therapeutics' Muscular Dystrophy Business

Acquisition supports Servier's strategic ambition in rare neurology with sevasemten, a late-stage investigational treatment for Becker and Duchenne muscular dystrophies. The acquired asset and expert team strengthen Servier's commitment to innovate for patients with high unmet medical...

Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.